A regimen or plan of physical activities designed and prescribed for specific therapeutic goals. Its purpose is to restore normal musculoskeletal function or to reduce pain caused by diseases or injuries.
Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION.
A mitochondrial cytochrome P450 enzyme that catalyzes the 1-alpha-hydroxylation of 25-hydroxyvitamin D3 (also known as 25-hydroxycholecalciferol) in the presence of molecular oxygen and NADPH-FERRIHEMOPROTEIN REDUCTASE. This enzyme, encoded by CYP27B1 gene, converts 25-hydroxyvitamin D3 to 1-alpha,25-dihydroxyvitamin D3 which is the active form of VITAMIN D in regulating bone growth and calcium metabolism. This enzyme is also active on plant 25-hydroxyvitamin D2 (ergocalciferol).
9,10-Secoergosta-5,7,10(19),22-tetraene-3,25-diol. Biologically active metabolite of vitamin D2 which is more active in curing rickets than its parent. The compound is believed to attach to the same receptor as vitamin D2 and 25-hydroxyvitamin D3.
A vitamin that includes both CHOLECALCIFEROLS and ERGOCALCIFEROLS, which have the common effect of preventing or curing RICKETS in animals. It can also be viewed as a hormone since it can be formed in SKIN by action of ULTRAVIOLET RAYS upon the precursors, 7-dehydrocholesterol and ERGOSTEROL, and acts on VITAMIN D RECEPTORS to regulate CALCIUM in opposition to PARATHYROID HORMONE.
The major circulating metabolite of VITAMIN D3. It is produced in the LIVER and is the best indicator of the body's vitamin D stores. It is effective in the treatment of RICKETS and OSTEOMALACIA, both in azotemic and non-azotemic patients. Calcifediol also has mineralizing properties.
A type of strength-building exercise program that requires the body muscle to exert a force against some form of resistance, such as weight, stretch bands, water, or immovable objects. Resistance exercise is a combination of static and dynamic contractions involving shortening and lengthening of skeletal muscles.
Hydroxy analogs of vitamin D 3; (CHOLECALCIFEROL); including CALCIFEDIOL; CALCITRIOL; and 24,25-DIHYDROXYVITAMIN D 3.
A hard or leathery calciferous exterior covering of an egg.
Carbonic acid calcium salt (CaCO3). An odorless, tasteless powder or crystal that occurs in nature. It is used therapeutically as a phosphate buffer in hemodialysis patients and as a calcium supplement.
Derivatives of ERGOSTEROL formed by ULTRAVIOLET RAYS breaking of the C9-C10 bond. They differ from CHOLECALCIFEROL in having a double bond between C22 and C23 and a methyl group at C24.
A specialized CONNECTIVE TISSUE that is the main constituent of the SKELETON. The principle cellular component of bone is comprised of OSTEOBLASTS; OSTEOCYTES; and OSTEOCLASTS, while FIBRILLAR COLLAGENS and hydroxyapatite crystals form the BONE MATRIX.
Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.
An NAPH-dependent cytochrome P450 enzyme that catalyzes the oxidation of the side chain of sterol intermediates such as the 27-hydroxylation of 5-beta-cholestane-3-alpha,7-alpha,12-alpha-triol.
A condition characterized by severe PROTEINURIA, greater than 3.5 g/day in an average adult. The substantial loss of protein in the urine results in complications such as HYPOPROTEINEMIA; generalized EDEMA; HYPERTENSION; and HYPERLIPIDEMIAS. Diseases associated with nephrotic syndrome generally cause chronic kidney dysfunction.
The presence of proteins in the urine, an indicator of KIDNEY DISEASES.
A kidney disease with no or minimal histological glomerular changes on light microscopy and with no immune deposits. It is characterized by lipid accumulation in the epithelial cells of KIDNEY TUBULES and in the URINE. Patients usually show NEPHROTIC SYNDROME indicating the presence of PROTEINURIA with accompanying EDEMA.
A characteristic symptom complex.
Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE.
A type of glomerulonephritis that is characterized by the accumulation of immune deposits (COMPLEMENT MEMBRANE ATTACK COMPLEX) on the outer aspect of the GLOMERULAR BASEMENT MEMBRANE. It progresses from subepithelial dense deposits, to basement membrane reaction and eventual thickening of the basement membrane.
A clinicopathological syndrome or diagnostic term for a type of glomerular injury that has multiple causes, primary or secondary. Clinical features include PROTEINURIA, reduced GLOMERULAR FILTRATION RATE, and EDEMA. Kidney biopsy initially indicates focal segmental glomerular consolidation (hyalinosis) or scarring which can progress to globally sclerotic glomeruli leading to eventual KIDNEY FAILURE.
The use of statistical methods in the analysis of a body of literature to reveal the historical development of subject fields and patterns of authorship, publication, and use. Formerly called statistical bibliography. (from The ALA Glossary of Library and Information Science, 1983)
A subspecialty of internal medicine concerned with the study of the physiology and diseases of the digestive system and related structures (esophagus, liver, gallbladder, and pancreas).
Copies of a work or document distributed to the public by sale, rental, lease, or lending. (From ALA Glossary of Library and Information Science, 1983, p181)
Critical and exhaustive investigation or experimentation, having for its aim the discovery of new facts and their correct interpretation, the revision of accepted conclusions, theories, or laws in the light of newly discovered facts, or the practical application of such new or revised conclusions, theories, or laws. (Webster, 3d ed)
"The business or profession of the commercial production and issuance of literature" (Webster's 3d). It includes the publisher, publication processes, editing and editors. Production may be by conventional printing methods or by electronic publishing.
Research that involves the application of the natural sciences, especially biology and physiology, to medicine.
A bibliographic database that includes MEDLINE as its primary subset. It is produced by the National Center for Biotechnology Information (NCBI), part of the NATIONAL LIBRARY OF MEDICINE. PubMed, which is searchable through NLM's Web site, also includes access to additional citations to selected life sciences journals not in MEDLINE, and links to other resources such as the full-text of articles at participating publishers' Web sites, NCBI's molecular biology databases, and PubMed Central.
The physiologically active form of vitamin D. It is formed primarily in the kidney by enzymatic hydroxylation of 25-hydroxycholecalciferol (CALCIFEDIOL). Its production is stimulated by low blood calcium levels and parathyroid hormone. Calcitriol increases intestinal absorption of calcium and phosphorus, and in concert with parathyroid hormone increases bone resorption.
A physiologically active metabolite of VITAMIN D. The compound is involved in the regulation of calcium metabolism, alkaline phosphatase activity, and enhances the calcemic effect of CALCITRIOL.
Proteins, usually found in the cytoplasm, that specifically bind calcitriol, migrate to the nucleus, and regulate transcription of specific segments of DNA with the participation of D receptor interacting proteins (called DRIP). Vitamin D is converted in the liver and kidney to calcitriol and ultimately acts through these receptors.
Cholecalciferols substituted with two hydroxy groups in any position.
Derivative of 7-dehydroxycholesterol formed by ULTRAVIOLET RAYS breaking of the C9-C10 bond. It differs from ERGOCALCIFEROL in having a single bond between C22 and C23 and lacking a methyl group at C24.
A publication issued at stated, more or less regular, intervals.
A polypeptide hormone (84 amino acid residues) secreted by the PARATHYROID GLANDS which performs the essential role of maintaining intracellular CALCIUM levels in the body. Parathyroid hormone increases intracellular calcium by promoting the release of CALCIUM from BONE, increases the intestinal absorption of calcium, increases the renal tubular reabsorption of calcium, and increases the renal excretion of phosphates.
Reduction of the blood calcium below normal. Manifestations include hyperactive deep tendon reflexes, Chvostek's sign, muscle and abdominal cramps, and carpopedal spasm. (Dorland, 27th ed)
Databases devoted to knowledge about PHARMACEUTICAL PRODUCTS.
The metabolism of drugs and their mechanisms of action.
Databases devoted to knowledge about specific chemicals.
Drugs intended for human or veterinary use, presented in their finished dosage form. Included here are materials used in the preparation and/or formulation of the finished dosage form.
The study of the origin, nature, properties, and actions of drugs and their effects on living organisms.
The process of finding chemicals for potential therapeutic use.
Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs.
Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.
6-carbon straight-chain or branched ketones.
A promyelocytic cell line derived from a patient with ACUTE PROMYELOCYTIC LEUKEMIA. HL-60 cells lack specific markers for LYMPHOID CELLS but express surface receptors for FC FRAGMENTS and COMPLEMENT SYSTEM PROTEINS. They also exhibit phagocytic activity and responsiveness to chemotactic stimuli. (From Hay et al., American Type Culture Collection, 7th ed, pp127-8)
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
A human cell line established from a diffuse histiocytic lymphoma (HISTIOCYTIC LYMPHOMA, DIFFUSE) and displaying many monocytic characteristics. It serves as an in vitro model for MONOCYTE and MACROPHAGE differentiation.
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in leukemia.
Procedures that avoid use of open, invasive surgery in favor of closed or local surgery. These generally involve use of laparoscopic devices and remote-control manipulation of instruments with indirect observation of the surgical field through an endoscope or similar device.
That portion of the body that lies between the THORAX and the PELVIS.
An abnormal balloon- or sac-like dilatation in the wall of the ABDOMINAL AORTA which gives rise to the visceral, the parietal, and the terminal (iliac) branches below the aortic hiatus at the diaphragm.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Surgical insertion of BLOOD VESSEL PROSTHESES to repair injured or diseased blood vessels.
Device constructed of either synthetic or biological material that is used for the repair of injured or diseased blood vessels.

Vitamin D status in different subgroups of British Asians. (1/491)

To assess the effect of religious dietary practices and social customs on the vitamin D status of Asian immigrants, we kept records of the dietary intake and time spent out of doors of 81 Ugandan Asian men, women, and girls (9-19 years old). Sera were analysed for 25-hydroxycholecalciferol (25-OHD3), and 28% of the subjects were found to have levels below the lower limit of normal. The (vegetarian) Hindus had the lowest dietary intakes, least time out of doors, and lowest serum 25-OHD3. The Goan (Roman Catholic) Asians, despite more pigmentation, had 25-OHD3 levels similar to those found among indigenous British people and had the most satisfactory vitamin D intakes. Among Asians, whose exposure to sunlight may be limited, dietary vitamin D becomes the major determinant of serum 25-OHD3.  (+info)

Clinical and subclinical vitamin D deficiency in Bradford children. (2/491)

A survey of the vitamin D status of Bradford schoolchildren was carried out in April 1973, employing conventional biochemistry, radiology, and measurement of 25-hydroxycholecalciferol levels. Biochemical evidence of rickets was present in 45% of the Asians. When re-examined in September, several children showed spontaneous biochemical resolution; nevertheless, radiological abnormalities were present in 12% of the original sample. No evidence of rickets was detected in the smaller White sample. Minor biochemical abnormalities were present in 9 of the 40 West Indian children. A study of admissions of Bradford hospitals in the 4 years 1969-1972 inclusive confirmed that clinical vitamin D deficiency was confined to Asians except for a few cases of infantile rickets in White children. The probability that one Asian child in 40 may require admission during the period from birth to adolescence emphasizes the urgent need for the introduction of prophylactic measures.  (+info)

Evidence for the promotion of bone mineralization by 1alpha,25-dihydroxycholecalciferol in the rat unrelated to the correction of deficiencies in serum calcium and phosphorus. (3/491)

Concurrent administration of 1alpha,25-dihydroxycholecalciferol [1alpha,25-(OH)2-CC] to intact and thyroparathyroidectomized rats treated with ethane-1-hydroxy-1,1-diphosphonate (EHDP) prevented or reversed the EHDP-induced inhibition of bone mineralization as measured by changes in epiphyseal plate width and ash content of bone. An analog, 1alpha-droxycholecalciferol, was also effective. Recovery of bone after EHDP treatment was also significantly improved by administration of 1alpha,25-(OH)2-CC as evidenced by enhanced uptake of 45Ca by epiphyseal plates and decreased plate widths. Cholecalciferol (CC), ergocalciferol, dihydrotachysterol2, 5,6-trans-CC, 25-OH-CC, 5,6-Trans-25-OH-CC, and 1alpha24R,25-(OH)3-CC also blocked EHDP-induced epiphyseal plate widening, but required high, pharmacological dose levels. 24R,25- (OH)2-CC was inactive at doses up to 10 microgram/day. Since EHDP-treated rats are not deficient in calcium or phosphate, these data suggest that 1alpha,25-dihydroxycholecalciferol promoted bone mineralization independently of effects upon the intestinal absorption of calcium and phosphate.  (+info)

Demonstration of the rapid action of pure crystalline 1 alpha-hydroxy vitamin D3 and 1 alpha,25-dihydroxy vitamin D3 on intestinal calcium uptake. (4/491)

The biological effects of crystalline 1alpha-hydroxyvitamin D3 and crystalline 1alpha,25-dihydroxyvitamin D3 have been compared on the intestinal uptake of calcium-45 by everted duodenal gut sacs from rachitic rats. Peak calcium-45 uptake was observed 1 hr after intravenous administration and both crystalline vitamin D2 analogs were of comparable potency. The rapid onset of calcium-45 uptake and the rapid attainment of maximal calcium-45 transport suggests a direct effect of these crystalline analogs on the mucosal membranes of the intestinal cell.  (+info)

Cytoplasmic and nuclear binding components for 1alpha25-dihydroxyvitamin D3 in chick parathyroid glands. (5/491)

Specific binding of 1 alpha,25-dihydroxyvitamin D3 [1alpha,25-(OH)2D3] to macromolecular components in the cytoplasm and nucleus is demonstrated in parathyroid glands of vitamin-D-deficient chicks. The interaction of 1alpha,25-(OH)2D3 with the cytoplasmic binding component is of high affinity (Kd = 3.2 X 10(-10) M) and high specificity [1alpha,25-(OH)2D3 greater than 25-hydroxyvitamin D3 greater than 1alpha-hydroxyvitamin D3 greater than vitamin D3 in competing with radioactive 1alpha,25-(OH)2D3]. Both cytoplasmic and nuclear hormone-macromolecular complexes sediment at 3.1 S in 0.3 M KC1-sucrose gradients, and agarose gel filtration of the components indicates an apparent molecular weight of 58,000. The 3.1S binding molecules are not observed in adrenal gland, testes, liver, or kidney, but similar receptors for 1alpha,25-(OH)2D3 have been found previously in intestine. Macromolecular species with a high affinity and preference for 25-hydroxyvitamin D3 [25-(OH)D3] are also identified in parathyroid cytosol and differ from the parathyroid 1alpha,25-(OH)2D3-binding component in that: (1) they sediment at 6 S in 0.3 M KC1-sucrose gradients, (2) they are observed in all tissues examined, (3) they have a higher affinity for 25-(OH)D3 than 1alpha,25-(OH)2d3, and (4) they are not found in the nucleus of the parathyroid glands, in vitro. The discovery of unique 1alpha,25-(OH)2D3-binding components in the parathyroid glands is consistent with the sterol hormone's action at this endocrin site and possible involvement in the regulation of parathyroid hormone synthesis and secretion.  (+info)

1Alpha-hydroxyvitamin D3 prevents the decrease of bone mineral density in lactating beagles. (6/491)

We assessed the change of bone mineral density (BMD) in lactating beagles with dual energy X-ray absorptiometry (DXA) and the preventive effect of 1alpha-hydroxyvitamin D3 (1alpha(OH)D3) on the BMD. Beagles, two to five years old, were used for detecting the time course change of BMD. Since the coefficient of variation (CV(%)) on detecting lumber vertebral (L2-L4) and tibial BMD by DXA was about 0.5%, DXA was useful to detect the change of BMD in beagles. There was a marked decrease in vertebral BMD during lactational period in the control group. The BMD levels after weaning were found to reverse to the initial level at mating. The same tendency was observed in tibial BMD as vertebral BMD, though the BMD changes were not marked. Beagles were administered at a dose of 0.1 microg/kg of 1alpha(OH)D3 three times in a week, and it was found to suppress the decrease in vertebral BMD during the breast feeding period. Also, the administration of 1alpha(OH)D3 promoted the prevention of decreased BMD during lactation both in vertebrae and tibiae. Significant effects of 1alpha(OH)D3 administration on tibial BMD were not observed. No adverse effects, such as hypercalcemia and hypercalciuria, were observed during the experimental period. Therefore, DXA was useful for detecting the changes of BMD in lactating beagles and the change of BMD was marked in lumber vertebrae, which are rich in trabecular bone. The preventive effect of 1alpha(OH)D3 on the decrease of BMD during the lactation period was observed in beagles.  (+info)

Vitamin D metabolite requirements in dialysed children receiving recombinant human growth hormone. (7/491)

BACKGROUND: The aim of the study was to assess the requirement of active vitamin D in dialysed children during treatment with recombinant human growth hormone (rhGH). METHODS: Twenty-six children (aged 5-15 years) were treated with rhGH for 6 months. The serum concentration of parathyroid hormone (PTH), alkaline phosphatase (AP), and calcium and phosphorus were measured in two groups of patients studied in the years 1994-1995 (group I) and 1995-1998 (group II) respectively. Group I received a constant dose of alfacalcidol that was sufficient to keep PTH below 200 pg/ml before rhGH treatment began. The serum PTH level was checked every 3 months. Alfacalcidol was administered to group II according to serum PTH levels checked on a monthly basis. RESULTS: In group I the PTH level increased after 3 and 6 months of rhGH treatment from mean level 73+/-60; 155+/-156 and 344+/-249 pg/ml respectively; P<0.05. AP activity increased after 6 months of treatment from 206+/-99 to 325+/-124 U/l respectively; P<0.01. The calcium level decreased from baseline after 3 months of treatment from 2.36+/-0.21 to 2.17+/-0.12 mmol/l respectively; P<0.05. In group II AP activity increased after 3 and 6 months of treatment from 272+/-169 to 332+/-192 and 404. 9+/-219.8 U/l respectively; P<0.01. The mean level of phosphorus decreased after 6 months from 2.15+/-0.28 to 1.70+/-0.39 mmol/l respectively; P<0.01. In group II the mean dose of alfacalcidol increased by 60.9%. CONCLUSIONS: In children with end-stage renal failure, higher doses of vitamin D are needed during rhGH treatment. During rhGH treatment, frequent control of serum PTH level is necessary.  (+info)

Osteomalacia that became symptomatic 13 years after a total gastrectomy. (8/491)

A 66-year-old man who underwent a total gastrectomy 13 years ago was admitted to our hospital complaining of severe low back pain and muscle weakness. Biochemical examinations revealed hypocalcemia, hypophosphathemia, low serum 25 (OH) vitamin D and hyperparathyroidism. A chest CT scan revealed pseudofractured ribs, whereas plain X-photography did not show any significant findings. We diagnosed the illness as osteomalacia due to malabsorption. The patient has been receiving oral active vitamin D and calcium, and the pain and serum calcium and phosphate values have improved to the point that he can receive out-patient treatment.  (+info)

Alfacalcidol tablets brand name, tab alfacalcidol use, alfacalcidol tablets, alfacalcidol capsules 0.25mcg price in india, alfacalcidol 0.5 prospect, alfacalcidol capsules 0.25 mcg uses in hindi
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
Egg-shell calcium (Ca) is one of the effective Ca sources for bone metabolism. In the present study, we investigated whether egg-shell Ca had similar effects compared with calcium carbonate (CaCO3) when vitamin D3 (1alpha(OH)D3) treatment was given to an osteoporotic rat model. In both 1alpha(OH)D3- …
The invention provides a new vitamin D2 compound, 1α-hydroxy-24-epi-vitamin D2 and certain hydroxy-protected derivatives thereof. The new compound exhibits a distinctive activity pattern comprising high potency in stimulating intestinal calcium transport and little or no activity in inducing bone calcium mobilization or the differentiation of undifferentiated cells in culture, thereby evincing utility in the treatment of diseases characterized by loss of bone mass.
Find out how to take Alfacalcidol (drug) and its dose. Describes the best time to take the drug and precautions if any that should be followed.
Generic for One-alpha (Alfacalcidol) is a Vitamin. Buy now with us and save $55.00. InternationalDrugMart.com offers best quality medications at discount.
The effect of 1-alpha-hydroxycholecalciferol and parathyroidectomy on cardiovascular lesions in uraemia: an experimental study in the rat ...
EFFECTS OF ORAL ALFACALCIDOL ON MATURATION OF DENDRITIC CELLS IN GRAVES DISEASE PATIENTS: A DOUBLE-BLINDED RANDOMIZED CLINICAL TRIAL
Looking for 1,25-dihydroxycholecalciferol? Find out information about 1,25-dihydroxycholecalciferol. 1,25-dihydroxycholecalciferol, the form of vitamin D that is involved in intestinal absorption of Ca2+and Ca2+resorption by bone Explanation of 1,25-dihydroxycholecalciferol
Importance of 25-hydroxycholecalciferol (vitamin D) -Therapeutic target range for the body is at a high level. Check the level of 25-hydroxycholecalciferol (vitamin D) -Therapeutic target range and prevent health problems.
Parenteral 1,25-dihydroxycholecalciferol in hepatic osteomalacia.: Despite regular long-term parenteral vitamin D2 treatment, four patients with biliary cirrhos
Disclosed is a pharmaceutical composition in dosage unit form which comprises a dosage effective for the treatment of pains and pyrexia, hypertension, hypotension, hyperlipemia, inflammatory diseases or diseases due to the functional accentuation of thrombocytes of a compound of 24,25-dihydroxycholecalciferol and a pharmaceutical acceptable carrier or diluent therefor.
Cholecalciferol, better known as vitamin D3, is naturally produced in the skin of animals that results from a reaction to sunlight. Excessive amounts of cholecalciferol can have adverse, and even fatal effects.
Alfacip is used to treat osteoporosis and conditions with impairments of calcium metabolism such as bone loss due to age. 0.5/mcg 0.25/mg.
ninfo.se medforsk laboratories ninfo.se Research and development guarantees/certificates Research & Studies: Cholecalciferol "Do not tell ever...
AMBICA PHARMA - Manufacturer,Supplier,Exporter of Colloidal Calium Cholecalciferol from India. We offer best quality of products at a best price rate.
Send os din e-mailadresse, så du kan få besked når produktet er tilbage på lager. Hvis produktet ikke bliver tilgængelig igen, vil vi underrette dig om mulige alternativer.. ...
To evaluate the efficacy and safety of alendronate, a double-masked, active (alfacalcidol) controlled comparative study for 48 weeks was carried out in a total of 210 Japanese patients with osteoporosis. The doses of alendronate and alfacalcidol were 5 mg/day and 1 microgram/day, respectively. The l …
Product Page for D 1000 IU (Cholecalciferol) 90 Tabs made by thompson offering price, ingredients and full item description from betterlife
Easy to read patient leaflet for Cholecalciferol Wafer. Includes indications, proper use, special instructions, precautions, and possible side effects.
Easy to read patient leaflet for Cholecalciferol Sublingual Spray. Includes indications, proper use, special instructions, precautions, and possible side effects.
On occasion, horses will come into contact with horse feed that has been contaminated with cholicalciferol, an active ingredient in many types of rat poison. Learn the signs of this type of poisoning and the common ways to treat it.
Boc Sciences offers cas 40013-87-4 24, 25-Dihydroxy VD3 in bulk,please inquire us to get a quote for 40013-87-4 24, 25-Dihydroxy VD3.
In the context of the global prevalence of vitamin D insufficiency, we compared two key determinants of the bioavailability of 3 vitamin D forms with significant biopotencies: cholecalciferol, 25-hydroxycholecalciferol and 1-α-hydroxycholecalciferol. To this aim, we studied their incorporation into synthetic mixed micelles and their uptake by intestinal cells in culture. Our results show that 1-α-hydroxycholecalciferol was significantly more solubilized into mixed micelles compared to the other forms (1.6-fold and 2.9-fold improvement compared to cholecalciferol and 25-hydroxycholecalciferol, respectively). In Caco-2 TC7 cells, the hydroxylated forms were taken up more efficiently than cholecalciferol (p | 0.05), and conversely to cholecalciferol, their uptake was neither SR-BI(Scavenger-Receptor class B type I)- nor NPC1L1 (NPC1 like intracellular cholesterol transporter 1)-dependent. Besides, the apical membrane sodium-bile acid transporter ASBT (Apical Sodium-dependent Bile acid Transporter) was
1,25-DHCC, 1,25-dihydroxy-22-ovavitamin D(3), 1,25-dihydroxycholecalciferol, 1,25-dihydroxy-vitamin-D (1,25(OH)(2)D), 1,25-dihydroxyvitamin D3, 1,25-diOHC, 1,25(OH) 2D3, 1-alpha (OH) D3, 19-nor-1, 1-alpha-hydroxycholecalciferol, 1-alpha-hydroxyvitamin D2, 1-hydroxyvitamin D, 22-oxacalcitriol (OCT), 24,25(OH)(2)vitamin D(3), 25 hydroxyvitamin D (25(OH)D), 25-dihydroxyvitamin D2, 25-dihydroxyvitamin D2, 19-nor-1, 25-HCC, 25-hydroxycholecalciferol, 25-hydroxyvitamin D, 25-hydroxyvitamin D3, 25-OHCC, 25-OHD3, activated 7-dehydrocholesterol, activated ergosterol, alfacalcidol, calcifediol, calcipotriene, calcipotriol, calcitriol, cholecalciferol, colecalciferol, cod liver oil, dichysterol, dihydrotachysterol, dihydrotachysterol 2, doxercalciferol, ecocalcidiol, ED-21 (vitamin D analog), ED-71 (vitamin D analog), ergocalciferol, ergocalciferolum, falecalcitrol, hexafluoro-1,25dihydroxyvitamin D3, irradiated ergosterol, maxacalcitol, MC903, Ostelin , paracalcin, paricalcitol, tacalcitol, Vi-delta ...
Secondary hyperparathyroidism has a significant impact on morbidity and mortality in advanced chronic kidney disease (CKD).Both nonselective and selective vitamin D receptor activators (VDRAs) are demonstrated in many studies for their efficacy on suppression of PTH. Most of them are quite expensive and unavailable in many countries. Calcitriol and alfacalcidol are less expensive and worldwidely distributed. There is only one short-term study which directly compares these two drugs. This study demonstrates that calcitriol is superior to alfacalcidol. However, alfacalcidol is a prohormone of calcitriol. It has to be converted by 25-hydroxylase at the liver to generate 1,25-dihydroxyvitamin D3 to act on target cells. Many pharmacokinetics studies demonstrate that alfacalcidol has lower AUC compared to calcitriol if they are administered in the same dose. Therefore, the authors hypothesize that alfacalcidol may be equivalently efficacious as calcitriol if its dose is adjusted according to the ...
M. A. Preece, J. L. H. ORiordan, D. E. M. Lawson, S. Edelstein, E. Kodicek; Studies of the Kinetics of Competitive Protein Binding Assays of Cholecalciferol and of 25-Hydroxycholecalciferol. Clin Sci 1 April 1972; 42 (4): 16P-17P. doi: https://doi.org/10.1042/cs042016Pb. Download citation file:. ...
Abstract: After a seven day depletion period of vitamin D supplementation beginning on day of hatch, male chicks of a commercial broiler strain were placed on diets supplemented with either a commercial source of 25-hydroxycholecalciferol (25-OH-D3) or a new source derived from fermentation. Levels of 0, 2.5, 5, 10, 20, 40, 60 and 80 μg/kg of each source were added to a common basal diet that was considered as marginal in calcium and phosphorus content. Each diet was fed to six pens of five birds each. Birds were then grown to 21 d of age at which time body weight and feed consumption were determined. All birds were euthanized by CO2 inhalation and all toes were removed and ashed. The right tibia was subjected to bone ash determination while the left tibia was subjected to break force analysis. Analysis of the data indicated no significant differences in performance between chicks fed the two sources of 25-OH-D3 (p,0.05) although numerical differences in weight gain and feed conversion were ...
Tacalcitol | VDR agonist | PRI 2191 | 1α,24-Dihydroxycholecalciferol | PRI2191 | CAS [57333-96-7] | Axon 2516 | Axon Ligand™ with >98% purity available from supplier Axon Medchem, prime source of life science reagents for your research
BACKGROUND We conducted the present study to investigate the therapeutic effects of a combination treatment of alfacalcidol (ALF) and risedronate (RIS) on the bone mechanical properties of bone and calcium (Ca) metabolism using an ovariectomized (OVX) rat model of osteoporosis. METHODS Female Wistar rats were OVX- or sham-operated at 40 weeks of age. Twelve weeks post-surgery, rats were randomized into seven groups: 1) sham + vehicle, 2) OVX + vehicle, 3) OVX + ALF 0.025 microg/kg/day, 4) OVX + ALF 0.05 microg, 5) OVX + RIS 0.3 mg, 6) OVX + RIS 3.0 mg, 7) OVX + ALF 0.025 microg + RIS 0.3 mg. Each drug was administered orally five times a week for 12 weeks. After treatment, we evaluated the mechanical properties of the lumbar vertebra and femoral midshaft. In the lumbar vertebra, structural and material analyses were performed using micro-computed tomography (micro-CT) and microbeam X-ray diffraction (micro-XRD), respectively. Biochemical markers in serum and urine were also determined. RESULTS (1)
For the ASCO study, researchers defined insufficiency as 25-hydroxy-vitamin D [25(OH)D] less than 30 ng/ml and deficiency as levels less than 20 ng/ml. Clinical guidelines recommend that level or even higher, with some suggesting vitamin D levels between 40 ng/ml and 60 ng/ml might be best ...
According to Natural News, there is evidence that stress, fatigue and depression are connected to low serum levels of vitamin D, in addition to known immunity, illness and disease issues. The more up-to-date integrative or holistic MDs and naturopaths recognize that 25-hydroxy-vitamin D or 25(OH)D3 test serum levels should be in the range of 50…
The concentration of inorganic sulfate-sulfur in the serum of vitamin D-deficient rats, 2.6 to 3.5 mg. per cent, was found to be higher than that in the serum o
Cholecalciferol, also called vitamin D-3, is a fat-soluble vitamin that is necessary for the maintenance of a healthy body. Your body makes cholecalciferol when your skin is exposed to ultraviolet rays from the sun, according to MayoClinic.com.
Toan T, Ryan RC, Simon GL, Calabrese JC, Dahl LF. CRYSTAL-STRUCTURE OF 25-HYDROXY-VITAMIN D3 MONOHYDRATE - STEREOCHEMICAL ANALYSIS OF VITAMIN-D MOLECULES. Journal of the Chemical Society-Perkin Transactions 2. 1977 :393-401. ...
Calcitriol (1,25-dihydroxycholecalciferol), the active form of vitamin D is known to have anti-tumor activity both in vitro and in vivo in a wide variety of malignant cell types. Calcitriol is not only anti-proliferative ...
There are 30 fifteen-letter words containing A, 2C, E and F: CAPRIFOLIACEOUS CERTIFICATORIES CHOLECALCIFEROL ... RECODIFICATIONS SPEECHIFICATION SUBSPECIFICALLY. Every word on this site is valid scrabble words. See other lists, that start with or end with letters of your choice.
TY - JOUR. T1 - Effects of combined administration of alfacalcidol and risedronate on cancellous and cortical bone mass of the tibia in glucocorticoid-treated young rats. AU - Iwamoto, Jun. AU - Seki, Azusa. AU - Takeda, Tsuyoshi. AU - Yamada, Harumoto. AU - Sato, Yoshihiro. AU - Yeh, James K.. PY - 2008/1/1. Y1 - 2008/1/1. N2 - The purpose of the present study was to examine the effects of combined administration of alfacalcidol (ALF) and risedronate (RIS) on cancellous and cortical bone mass of the tibia in glucocorticoid (GC)-treated young rats. One hundred and nine female Sprague-Dawley rats, 3 months of age, were randomly divided by the stratified weight method into eleven groups according to the following treatment schedule: baseline control, a 4-week age-matched control, and a 4-week GC administration with a 4-week concomitant administration of vehicle, ALF, RIS, or ALF+RIS, and an 8-week age-matched control and 8-week GC administration with a 4-week administration of vehicle, ALF, RIS, ...
O:13:\PanistOpenUrl\:36:{s:10:\\u0000*\u0000openUrl\;N;s:6:\\u0000*\u0000idc\;N;s:6:\\u0000*\u0000fmt\;s:7:\journal\;s:6:\\u0000*\u0000doi\;s:0:\\;s:6:\\u0000*\u0000pii\;s:0:\\;s:7:\\u0000*\u0000pmid\;s:0:\\;s:9:\\u0000*\u0000atitle\;s:139:\EFFECT OF 1,25-DIHYDROXYCHOLECALCIFEROL AND 1,25-DIHYDROXYCHOLECALCIFEROL GLYCOSIDE ON 2,3 DIPHOSPHOGLYCERATE LEVELS OF THE RAT ERYTHROCYTE\;s:9:\\u0000*\u0000jtitle\;s:0:\\;s:9:\\u0000*\u0000stitle\;s:0:\\;s:7:\\u0000*\u0000date\;s:4:\1980\;s:9:\\u0000*\u0000volume\;s:0:\\;s:8:\\u0000*\u0000issue\;s:0:\\;s:8:\\u0000*\u0000spage\;s:0:\\;s:8:\\u0000*\u0000epage\;s:0:\\;s:8:\\u0000*\u0000pages\;s:0:\\;s:7:\\u0000*\u0000issn\;s:0:\\;s:8:\\u0000*\u0000eissn\;s:0:\\;s:9:\\u0000*\u0000aulast\;s:7:\LOCATTO\;s:10:\\u0000*\u0000aufirst\;s:2:\ME\;s:9:\\u0000*\u0000auinit\;N;s:10:\\u0000*\u0000auinitm\;N;s:5:\\u0000*\u0000au\;a:7:{i:0;s:10:\LOCATTO ME\;i:1;s:12:\FERNANDEZ ...
TY - JOUR. T1 - Intestinal Calcium Transport in Spontaneously Hypertensive Rats (SHR) and Their Genetically Matched WKY Rats. AU - Shibata, Harumichi. AU - Ghishan, Fayez K.. PY - 1990/5. Y1 - 1990/5. N2 - Calcium transport across the basolateral membranes of the enterocyte represents the active step in calcium translocation. This step occurs by two mechanisms, an ATP-dependent pump and a Ca2+/Na+ exchange process. These studies were designed to investigate these two processes in jejunal basolateral membrane vesicles (BLMV) of the spontaneously hypertensive rats (SHR) and their genetically matched controls, Wistar-Kyoto (WKY) rats. The ATP-dependent calcium uptake was stimulated several-fold compared with no ATP condition in both SHR and WKY, but no differences were noted between rate of calcium uptake in SHR and WKY. Kinetics of ATP-dependent calcium uptake at concentrations between 0.01 and 1.0 μM revealed a V max of 0.67 ± 0.03 nmol/mg protein/20 sec and a Km of 0.2 ± 0.03 μM in SHR and V ...
Best quality Co-Enzyme Q 10 L Arginine L Carnitine Lycopene Alfacalcidol Piperion Omega 3 Fatty Acid Vitamins and Minerals Tablet, Buy from Co-Enzyme Q 10 L Arginine L Carnitine Lycopene Alfacalcidol Piperion Omega 3 Fatty Acid Vitamins and Minerals Tablet Manufacturer, Supplier in Ahmedabad, India.
The effects of hydroxylated derivatives of vitamin D3 and aqueous extracts of Solanum malacoxylon on the intestinal absorption of calcium, phosphate, sodium, potassium and water have been studied in unstressed vitamin D-replete pigs each of which was surgically prepared beforehand with a Thirty-Vella loop of jejunum. The addition, for six 1 h periods of perfusion, of 1,25-dihydroxycholecalciferol (1,25-(OH)2D3) or 1α-hydroxycholecalciferol at similar concentrations (3·6-3·75 pmol/ml) to the solution used to perfuse the intestinal loop caused a rapid increase in the absorption of calcium but increased the absorption of phosphate only after a delay of at least 12 h. The absorption of both calcium and phosphate reached a maximum on the day following the addition of the vitamin D derivative to the perfusate. The addition of 25-hydroxycholecalciferol (25-(OH)D3) at a concentration of 3·75 pmol/ml was without effect on absorption except for a small increase in the absorption of phosphate on the ...
The active vitamin D metabolite 1 25 D3 (1 25 has been proven to be a significant regulator of innate and adaptive immune function. gene appearance which treatment using a physiological focus of 25(OH)D3 down-regulated IFN-γ and IL-17F gene appearance ...
Retin a cream cost lithium sulfur battery buy where to buy kamagra oral jelly in melbourne nizoral shampoo by prescription capoten price in pakistan buy cheap sildalis dapoxetine uk plavix price
Cholecalciferol is a form of vitamin D thats synthesized by the skin after exposure to sunlight. Its also added to many foods as...
RATIONALE: The use of cholecalciferol and calcium carbonate may keep colon cancer from coming back in patients with colon cancer that has been removed b
TY - JOUR. T1 - The metabolism of 1,25-dihydroxyvitamin D3.. AU - Kumar, Rajiv. PY - 1980/6. Y1 - 1980/6. UR - http://www.scopus.com/inward/record.url?scp=0019030105&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=0019030105&partnerID=8YFLogxK. M3 - Article. C2 - 6894425. AN - SCOPUS:0019030105. VL - 1. SP - 258. EP - 267. JO - Endocrine Reviews. JF - Endocrine Reviews. SN - 0163-769X. IS - 3. ER - ...
Sigma-Aldrich offers abstracts and full-text articles by [Steve Y Rhieu, Andrew J Annalora, Guochun Wang, Caroline C Flarakos, Rose M Gathungu, Paul Vouros, Rita Sigüeiro, Antonio Mouriño, Inge Schuster, G Tayhas R Palmore, G Satyanarayana Reddy].
Thank you for your interest in spreading the word about Biochemical Journal.. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.. ...
There arent words to describe that feeling when you leave your house and start riding, to realise halfway through that you dont have a jacket on, and frankly, you dont care; the sun has graced us with its presence over the last week and it has been wonderful! Most of the weekend was spent at…
... hydroxycholecalciferols MeSH D10.570.938.146.478.250 - calcifediol MeSH D10.570.938.146.478.387 - dihydroxycholecalciferols ...
... hydroxycholecalciferols MeSH D04.808.247.222.159.478.250 - calcifediol MeSH D04.808.247.222.159.478.387 - ... hydroxycholecalciferols MeSH D04.808.247.808.146.478.250 - calcifediol MeSH D04.808.247.808.146.478.387 - ... hydroxycholecalciferols MeSH D04.808.812.768.196.478.250 - calcifediol MeSH D04.808.812.768.196.478.387 - ...
"Hydroxycholecalciferols" is a descriptor in the National Library of Medicines controlled vocabulary thesaurus, MeSH (Medical ... This graph shows the total number of publications written about "Hydroxycholecalciferols" by people in this website by year, ... Below are the most recent publications written about "Hydroxycholecalciferols" by people in Profiles. ... and whether "Hydroxycholecalciferols" was a major or minor topic of these publications. ...
Hydroxycholecalciferols. Alfacalcidol. Vitamins. Micronutrients. Growth Substances. Physiological Effects of Drugs. Bone ...
Hydroxycholecalciferols. Calcifediol. Vitamin D. Vitamins. Micronutrients. Growth Substances. Physiological Effects of Drugs. ...
Hydroxycholecalciferols / metabolism* * Lumbar Vertebrae / metabolism * Osteoporosis / metabolism* * Ovariectomy * Rats * Tibia ...
Hydroxycholecalciferols / blood* * Kidney Function Tests * Male * Middle Aged * Nephrotic Syndrome / blood * Nephrotic Syndrome ...
Hydroxycholecalciferols / therapeutic use*. Inflammation / drug therapy*. Kidney Failure, Chronic / mortality. Male. Middle ... 0/Hydroxycholecalciferols; 0/Receptors, Calcitriol; 1406-16-2/Vitamin D; 64719-49-9/25-hydroxyvitamin D; URQ2517572/ ...
Hydroxycholecalciferols [D04.808.247.222.159.478]. *Dihydroxycholecalciferols [D04.808.247.222.159.478.387]. *Sterols [D04.808. ...
Treated with 25 hydroxycholecalciferols and increase relevant illness with ECF KR101838328B1 (en) 2010-12-28. 2018-03-13. 퓨처 ...
... hydroxycholecalciferols MeSH D10.570.938.146.478.250 - calcifediol MeSH D10.570.938.146.478.387 - dihydroxycholecalciferols ...
... hydroxycholecalciferols MeSH D04.808.247.222.159.478.250 - calcifediol MeSH D04.808.247.222.159.478.387 - ... hydroxycholecalciferols MeSH D04.808.247.808.146.478.250 - calcifediol MeSH D04.808.247.808.146.478.387 - ... hydroxycholecalciferols MeSH D04.808.812.768.196.478.250 - calcifediol MeSH D04.808.812.768.196.478.387 - ...
Ansaloni, L., Pisano, M., Coccolini, F., Peitzmann, A. B., Fingerhut, A., Catena, F., Agresta, F., Allegri, A., Bailey, I., Balogh, Z. J., Bendinelli, C., Biffl, W., Bonavina, L., Borzellino, G., Brunetti, F., Burlew, C. C., Camapanelli, G., Campanile, F. C., Ceresoli, M., Chiara, O. & 32 others, Civil, I., Coimbra, R., De Moya, M., Di Saverio, S., Fraga, G. P., Gupta, S., Kashuk, J., Kelly, M. D., Koka, V., Jeekel, H., Latifi, R., Leppaniemi, A., Maier, R. V., Marzi, I., Moore, F., Piazzalunga, D., Sakakushev, B., Sartelli, M., Scalea, T., Stahel, P. F., Taviloglu, K., Tugnoli, G., Uraneus, S., Velmahos, G. C., Wani, I., Weber, D. G., Viale, P., Sugrue, M., Ivatury, R., Kluger, Y., Gurusamy, K. S. & Moore, E. E., 2016, In : World Journal of Emergency Surgery. 11, 1, p. 1-23 23 p.. Research output: Contribution to journal › Review article ...
TY - JOUR. T1 - The metabolism of 1,25-dihydroxyvitamin D3.. AU - Kumar, Rajiv. PY - 1980/6. Y1 - 1980/6. UR - http://www.scopus.com/inward/record.url?scp=0019030105&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=0019030105&partnerID=8YFLogxK. M3 - Article. C2 - 6894425. AN - SCOPUS:0019030105. VL - 1. SP - 258. EP - 267. JO - Endocrine Reviews. JF - Endocrine Reviews. SN - 0163-769X. IS - 3. ER - ...
Rats , Bone Density Conservation Agents/therapeutic use , Diphosphonates/therapeutic use , Hydroxycholecalciferols/therapeutic ... Hydroxycholecalciferols/pharmacology , Male , Middle Aged , Osteoporosis/drug therapy , Treatment Outcome ... Hydroxycholecalciferols/pharmacology , Male , Middle Aged , Osteoporosis/drug therapy , Treatment Outcome ...
Hydroxycholecalciferols/analysis*. *Hydroxycholecalciferols/blood. *Lactation. *Milk, Human/analysis*. *Pregnancy. *Vitamin D/ ...
Hydroxycholecalciferols. *Lymphokines. *Vascular Endothelial Growth Factor A. *Vascular Endothelial Growth Factors. *Calcitriol ...
hydroxycholecalciferols plural of hydroxycholecalciferol. → Definition and anagrams of hydroxycholecalciferols. → Other senses ...
TY - JOUR. T1 - The action of 1alphahydroxy vitamin D3 and phosphate supplements in hypophosphataemic osteomalacia.. AU - Peacock, M.. AU - Aaron, J. E.. AU - Heyburn, P. J.. AU - Nordin, B. E.. PY - 1977/1/1. Y1 - 1977/1/1. UR - http://www.scopus.com/inward/record.url?scp=0017329867&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=0017329867&partnerID=8YFLogxK. M3 - Article. C2 - 899935. AN - SCOPUS:0017329867. VL - 81. SP - 431. EP - 440. JO - Advances in Experimental Medicine and Biology. JF - Advances in Experimental Medicine and Biology. SN - 0065-2598. ER - ...
Humans , Adolescent , Adult , Aged , Adiposity , Body Composition , Hydroxycholecalciferols , Obesity/epidemiology , Vitamin D ... Child , Adult , Hydroxycholecalciferols , Maternal and Child Health , Nutritional Status , Osteomalacia , Rickets , Vitamin D ... Humans , Male , Hypoparathyroidism/drug therapy , Paresthesia , Muscle Cramp , Hydroxycholecalciferols , Calcium Carbonate , ... Adult , Aged , Continental Population Groups/statistics & numerical data , Female , Humans , Hydroxycholecalciferols/blood , ...
mh:"Vitamin D" OR mh:"Cholecalciferol" OR mh:"Hydroxycholecalciferols" OR mh:"Calcifediol" OR mh:"Dihydroxycholecalciferols" OR ... OR Cholecalciferol OR Colecalciferol OR Hydroxycholecalciferols OR Hidroxicolecalciferoles OR Hidroxicolecalciferois OR ...
D04.210.500.247.222.159.478 Hydroxycholecalciferols .. D04.210.500.247.222.159.478.387 Dihydroxycholecalciferols .. D04.210. ... D04.210.500.247.808.146.478 Hydroxycholecalciferols .. D04.210.500.247.808.146.478.387 Dihydroxycholecalciferols .. D04.210. ... D04.210.500.812.768.196.478 Hydroxycholecalciferols .. D04.210.500.812.768.196.478.387 Dihydroxycholecalciferols .. D04.210. ... D10.570.938.146.478 Hydroxycholecalciferols .. D10.570.938.146.478.387 Dihydroxycholecalciferols .. D10.570.938.146.478.387.300 ...
Bone and Bones, Humans, Bone Resorption, Osteitis Deformans, Calcium, Hydroxycholecalciferols, Alkaline Phosphatase, ...
AdultAnorexia NervosaBone and BonesCalcitoninCalciumCalcium-Binding ProteinsChildFemaleHomeostasisHumansHydroxycholecalciferols ...
ChildChronic Kidney Disease-Mineral and Bone DisorderDialysis SolutionsFibrous Dysplasia of BoneHumansHydroxycholecalciferols ...
Hydroxycholecalciferols. *Lipids. *Membrane Lipids. *Membrane Transport Modulators. *Micronutrients. *Misc. Skin and Mucous ...
InChI=1S/C30H46O3/c1-6-30(33,7-2)18-9-8-11-21(3)26-15-16-27-23(12-10-17-29(26,27)5)13-14-24-19-25(31)20-28(32)22(24)4/h8-9,11,13-14,18,21,25-28,31-33H,4,6-7,10,12,15-17,19-20H2,1-3,5H3/b11-8+,18-9+,23-13+,24-14-/t21-,25-,26-,27+,28+,29-/m1/ ...
Hydroxycholecalciferols - blood Infant Magnesium - blood Phosphorus - blood Pilot Projects Rickets - prevention & control Risk ...
Hydroxycholecalciferols: 18*Dihydroxycholecalciferols: 1*Calcitriol: 3262*1,25-dihydroxy-23-thiavitamin D3 ...
Hydroxycholecalciferols - blood - metabolism Kidney - metabolism Middle Aged Osteomalacia - blood - complications - etiology ...
  • Hydroxycholecalciferols" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings) . (umassmed.edu)
  • This graph shows the total number of publications written about "Hydroxycholecalciferols" by people in this website by year, and whether "Hydroxycholecalciferols" was a major or minor topic of these publications. (umassmed.edu)